Engineered Nanoparticles (ENP) are increasingly produced for use in a wide range of industrial and consumer products. Yet it is known that exposure to some types of particles can cause severe health effects. Therefore it is essent...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
miRNAno
Toxicogenomic studies on engineered carbon nanomaterials
192K€
Cerrado
NANOSOLUTIONS
Biological Foundation for the Safety Classification of Engin...
14M€
Cerrado
MODERN
MODeling the EnviRonmental and human health effects of Nanom...
1M€
Cerrado
PATROLS
Physiologically Anchored Tools for Realistic nanOmateriaL ha...
13M€
Cerrado
NADETOX
NAnomics in vitro DEvelopmental TOXcology
184K€
Cerrado
MOD-ENP-TOX
Modeling Assays Platform MAP for hazard ranking of engi...
1M€
Cerrado
Información proyecto ENPRA
Líder del proyecto
Edinburgh Innovations
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
5M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Engineered Nanoparticles (ENP) are increasingly produced for use in a wide range of industrial and consumer products. Yet it is known that exposure to some types of particles can cause severe health effects. Therefore it is essential to ascertain whether exposure to ENP can lead to possible health risks for workers and consumers. We have formed a consortium of well-known scientists from European Universities and Research Institutes, with over 100 publications in the field of Nanotoxicology. Our aim is to develop an approach for the Risk Assessment of ENP (ENPRA). Our objectives are: (i) to obtain a bank of commercial ENP with contrasting physico-chemical characteristics and measure them; (ii) to investigate the toxic effects of ENP on 5 (pulmonary, hepatic, renal, cardiovascular and developmental) target systems and 5 endpoints (oxidative stress, inflammation; immuno-toxicity; fibrogenecity; genotoxicity) using in vitro animal/human models; (iii) to validate the in vitro findings with a small set of carefully chosen in vivo animal experiments; (iv) to construct mathematical models to extrapolate the exposure-dose-response relationship from in vitro to in vivo and to humans; (v) to use QSAR like models to identify the key ENP characteristics driving the adverse effects; (vi) to implement a risk assessment of ENP using the Weight-of-Evidence approach; (vii) to disseminate our findings to potential stakeholders. To harmonise the research activities between our EU group and the US, we have established links with scientists from US Universities (Duke, Rochester) and Government Agencies (NIH/NIEHS, NIOSH and EPA) with on-going research in Nanotoxicology. Our objectives here are (vii) to share information and agree on experimental protocols; (viii) to avoid duplication of work; (ix) to further validate the findings of this proposed study.